Last update 08 May 2025

MUC17 x CD3 x CD28

Basic Info

Related Targets
MUC17CD3CD28

Related

1
Drugs associated with MUC17 x CD3 x CD28
SSS59
Target
CD28 x CD3 x MUC17
Mechanism
CD28 inhibitors [+2]
Active Org.
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
Originator Org.
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
Active Indication
Advanced cancer
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with MUC17 x CD3 x CD28
NCT06944444
/ RecruitingPhase 1
A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors
100 Clinical Results associated with MUC17 x CD3 x CD28
Login to view more data
100 Translational Medicine associated with MUC17 x CD3 x CD28
Login to view more data
0 Patents (Medical) associated with MUC17 x CD3 x CD28
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free